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Abstract.  
 
Background: Adjuvant chemotherapy is recommended as a treatment for women with high 
recurrence risk early breast cancer. Older women are less likely to receive chemotherapy 
than younger women. This study has investigated the impact of chemotherapy on breast 
cancer specific survival in women aged 70+ using English Registry data.  
 
Methods: Cancer registration data were obtained from two English regions from 2002 to 
2012 (n=29,728).  The impact of patient level characteristics on the probability of receiving 
adjuvant chemotherapy was explored using logistic regression. Survival modelling was 
undertaken to show the effect of chemotherapy and age/health status on breast cancer 
specific survival. Missing data was handled using multiple imputation. 
 
Results: 11,735 surgically treated early breast cancer patients were identified. Use of 
adjuvant chemotherapy has increased over time. Younger age at diagnosis, increased nodal 
involvement, tumour size and grade, oestrogen receptor negative or HER2 positive disease 
were all associated with increased probability of receiving chemotherapy. Chemotherapy 
was associated with a significant reduction in the hazard of breast cancer specific mortality 
in women with high recurrence risk cancer, after adjusting for patient level characteristics 
(Hazard Ratio 0.74, 95% CI 0.67-0.81).  
 
Discussion: Chemotherapy is associated with an improved breast cancer specific survival in 
older women with high recurrence risk early breast cancer. Lower rates of chemotherapy use 
in older women may, therefore, contribute to inferior cancer outcomes. Decisions on 
potential benefits for individual patients should be made on the basis of life expectancy, 
treatment tolerance and patient preference. 
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Introduction 
Breast cancer is the most commonly diagnosed cancer in the UK. Incidence rates increase 
with age with over 30% of cases diagnosed in women over 70(1) (2) . This proportion will 
increase as population life expectancy improves.  
 
Older cancer patients in the UK experience inferior access to cancer services and 
treatments compared with younger patients(3-5). Audits of routinely collected cancer registry 
data(3) and cohort studies have shown lower rates of chemotherapy for older women 
compared with younger women with breast cancer in the UK and US and wide regional 
variation in these rates(3,6,7,8,9). The difference in chemotherapy rates by age has been 
maintained over time. In 2006 16% of women over the age of 70 received chemotherapy 
compared with 38% aged 50-70(10). Between  2014 and 2016 rates for women with ER – 
disease were 23% for those aged 70+ years compared with 61% for 50–69 years (3).   
Furthermore, UK relative survival in older women with breast cancer is worse compared with 
many other developed nations including Belgium, Poland, Ireland and the Netherlands(11,12).   
There is a clear need for research to elucidate how treatment decisions are made for older 
UK patients and how current practice is contributing to inferior outcomes.   
 
   
Adjuvant chemotherapy is usually recommended for high recurrence risk early breast cancer 
patients.  This usually includes patients with adverse tumour biology (oestrogen receptor 
(ER) negative, human epidermal growth factor receptor 2 (HER2) positive, high grade, high 
risk genomic array scores) and more advanced stage, according to complex algorithms. The 
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)(13) reported that surgery with 
adjuvant poly-chemotherapy was associated with a reduced risk of recurrence (12%) and 
death (13%) in patients aged 70+, compared with surgery without adjuvant chemotherapy. 
However, uncertainty in these estimates was large due to the small number of older breast 
cancer patients recruited in the trials and unplanned subgroup analyses are prone to bias. 
 There are several reasons why older women may not receive chemotherapy: They are more 
likely to have chronic co-morbidities and/or frailty, which can reduce their tolerance and 
resilience to treatment.   For some, it may be judged that survival benefits from 
chemotherapy are small in comparison to potential side effects if life expectancy is 
compromised(14,15). Older women are more likely to have ER positive disease which is(16, 17) 
associated with improved prognosis and treatable with adjuvant endocrine therapy.  
 
The rates and severity of adverse effects from chemotherapy are higher in older women. In 
one analysis of women >70 receiving chemotherapy, the rate of febrile neutropenia was 19% 
and the treatment discontinuation rate was 23%. This was higher than observed in clinical 
trials where rates for age 65+ have been reported in the range 4% to 9% and rates for <60 at 
2.5% (18). Febrile neutropenia is a life-threatening toxicity in all patients, but particularly older 
patients where co-morbidities may further compromise outcomes. Adjuvant trastuzumab 
improves outcomes in HER2+ breast cancer(19) but is associated with cardiac toxicity. This 
risk, particularly when given alongside anthracycline-based chemotherapy, appears 
particularly pronounced in older women(20).Therefore, any decision to offer adjuvant 
chemotherapy to older women must consider not just the benefits in terms of disease 
recurrence, but immediate and long-term risks of toxicity.  
 
   
Formulation of evidence-based chemotherapy guidelines for early breast cancer in older 
women requires evaluation of current routine practice and outcomes. This study consists of 
a retrospective analysis of routinely collected patient level data for breast cancer patients 
aged 70+ from two English cancer registry regions, diagnosed between 2002 and 2012. The 
analysis consists of two parts. Firstly, associations between patient level factors and the 
decision to offer adjuvant chemotherapy are analysed using descriptive and statistical 
methods. Trends in chemotherapy use over this period are also reported. Secondly, a 
survival analysis describes how breast-cancer specific survival differs between patients 
treated with and without chemotherapy.  
 
Methods 
 
Cancer registration records were acquired for all new breast cancer diagnoses in women 
aged 70+ between 2002-12 within two English registration regions (West Midlands and 
Northern & Yorkshire), covering approximately 25% of the UK population. This cohort is 
broadly representative of the overall UK demography. Patients under the age of 70 at 
diagnosis were excluded from analysis, as were women who had no surgery (i.e. those who 
were treated with primary endocrine therapy. 49 patients (0.4% of those analysed) with a 
history of breast cancer prior to their index diagnosis were included. Variables in the dataset 
included age and date at diagnosis, screening or symptomatic presentation, tumour 
characteristics (size, nodal staging, grade, ER, HER2 and progesterone receptor (PR) 
status), and information on treatment episodes (date and type of treatment). Comorbidity 
was derived from linked Hospital Episode Statistics (HES) records as described 
elsewhere(21) and aggregated into a proxy for the Charlson Comorbidity Index (CCI). Income 
domain data from the Office for National Statistics (ONS) Indices of Multiple Deprivation 
were also analysed. English indices of deprivation (2010) were derived from linked 
postcodes. Dates and causes of death were linked from ONS death certification data. 
Deaths coded as other than “breast cancer” were treated as non-breast cancer deaths. 
 
Analyses were restricted to women diagnosed with stage I-III disease, treated with surgery 
to the primary tumour within 6 months of diagnosis. Patients with missing stage were 
included given that surgery would unlikely be offered if metastases were detectable at 
diagnosis. Individuals were categorised as receiving “adjuvant chemotherapy” (“CT”) or “no 
chemotherapy” (“No CT”) according to whether they had a treatment episode including 
chemotherapy within 6 months of surgery, although in some cases the chemotherapy may 
have been neoadjuvant. No subgroup analysis was performed regarding whether 
neoadjuvant or adjuvant chemotherapy was given on the basis that RCT evidence indicates  
that there is no survival  difference between these two pathways(22).  Some analyses were 
restricted to patients at high risk of recurrence, based on criteria adopted from the AChEW 
study (at least one of the following; the primary tumour is ER-, is HER2+, is grade III, or 
there is nodal involvement in at least 4 regional lymph nodes ) (6).  Each patient was also 
given a risk category score in the range 1-4, being the number of these risk indicators 
present for the patient.  
 
To investigate temporal trends, the chemotherapy rate was plotted against diagnosis year for 
patients aged 70-79. Associations between patient and disease characteristics were 
assessed using logistic regressions. Survival models were estimated for breast cancer 
specific survival (BCSS). Patients were censored at the date of death from other causes. 
Patients alive on 17/01/17 had survival time censored at this date. Survival outcomes for 
patients treated with and without chemotherapy were compared using cumulative incidence 
plots. A more nuanced understanding of survival was obtained by plotting survival curves for 
patients with increasing levels of risk category score (as defined above). 
 
Associations between patients, treatment characteristics and survival were investigated 
using multivariate proportional hazard regression, using Royston-Parmar restricted cubic 
spline parametric models (23). The Royston-Parmar model is more flexible than the Cox 
Proportional Hazards model, relaxing the proportional hazards assumption for some 
variables by allowing the effect of that covariate to vary over time. It also specifies a flexible 
functional form for the underlying hazard, making it easier to extrapolate to predictions of 
future outcomes. (Additional details in supplementary materials, Figure S1). On the basis of 
exploratory analysis the effect of age at diagnosis was modelled as time varying and the 
others covariates were modelled as time invariant.  
 
Some patients have incomplete data. It was known that some of the parameters which had 
high levels of missing data (for example, tumour grade, tumour size, nodal status) were 
more likely to be missing for patients who received PET and therefore had not had surgery. 
To mitigate against bias and the reduction in precision associated with deletion of incomplete 
cases, multiple imputation with chained equations (MICE) was used to produce 25 complete 
replications of the dataset. All logistic regression and survival models were applied to each 
of these datasets and the results were then combined to derive the final model (24). Variables 
with over 50% missing data were excluded from the analysis.  Supplementary material, 
Tables S1 and S2 give further details of the data pre-processing and multiple imputation 
processes.  
 
Royston-Parmar models were estimated in Stata (25) using the package sptm2(23). All other 
analyses were carried out using the statistical software package R (version 3.3.2)(26). The 
user-contributed packages “mice” (27), “survival” (28)) and “ggplot2” (29) were used to 
implement the MICE algorithm, survival analyses and plots respectively. 
 
RESULTS 
 
Between 2002-12, 29,728 women were diagnosed with breast cancer and of these 11,735 
were identified with stage I-III (or unknown) disease, treated with surgery within 6 months of 
diagnosis and included in this analysis (Figure 1).  Patients receiving chemotherapy tended 
to be younger, with fewer comorbidities and had higher recurrence risk disease. Very few 
patients aged 80+ received chemotherapy, precluding meaningful analysis for this age group  
(N=122, <1%) (Figure 2); subsequent analyses were restricted to patients aged 70-79 at 
diagnosis. Table 1 shows patient characteristics for those aged 70 to 79, split by treatment. 
 
There was evidence of increasing use of chemotherapy over time for the entire cohort and 
for those categorised as high risk (Figure 3). The logistic regression results are shown in 
Table 2. Younger age at diagnosis (Odds ratio (OR) 0.76 per year >70, 95%CI 0.74-0.79), 
increased nodal involvement (OR 1-3 nodes 3.74, 3.12-4.48; 4+ nodes 7.21, 5.97-8.72), 
tumour size (OR 1.015 per mm, 1.011-1.019) and grade (OR Grade 2: 2.68, 1.74-4.13, 
Grade 3: 6.33, 4.11-9.75), or having HER2+ disease (OR 2.90, 2.48-3.41) were all 
associated with increased probability of receiving chemotherapy. Having ER+ disease (OR 
0.31, 0.26-0,36) was associated with a lower probability of receiving chemotherapy. 
 
 
Naive comparison of survival outcomes between the two treatment groups showed that 
BCSS and short term OS were worse for patients who received chemotherapy (Results not 
shown). However, this arises from the difference in risk profiles between the two treatment 
groups (Figures 4 and 5).  Figure 4 shows the profile of high risk members of the treatment 
and non-treatment groups when they were also given a score based on the number of high 
risk indicators they had (one each for ER-, HER2+, grade 3, and 4 or more nodes involved).  
The majority of no-chemotherapy patients have only one risk indicator, whilst the majority of 
patients receiving chemotherapy have two or more. Patients receiving CT tended to have a 
higher risk score than those not treated. Figure 5 shows BCSS by risk group. When all 
patients with at least one high risk indicator were considered, chemotherapy was still 
associated with reduced BCSS. However, the two groups of patients (chemotherapy and no 
chemotherapy) may still have had markedly different characteristics which may have 
influenced their prognosis. When the analysis was repeated with only higher risk scoring 
patients (2+), the positive effect of chemotherapy becomes clear, even when allowing for the 
uncertainty caused by comparing fewer patients.  
 
The more sophisticated analysis undertaken using the Royston-Parmar model, which takes 
account of the differing patient level characteristics between the chemotherapy and no 
chemotherapy treatment groups, shows that chemotherapy is associated with a significant 
reduction in the hazard of breast cancer specific mortality (Hazard ratio 0.74, 95% CI 0,67-
0.81, Table 3).  
 
DISCUSSION 
This study found that chemotherapy was associated with a reduction in breast cancer 
specific mortality for patients aged 70-79 treated surgically for breast cancer in two English 
regions, after adjustment for patient level characteristics. Current UK guidance states that 
chemotherapy should be considered for all women with disease characteristics indicating a 
high risk of recurrence(30).This is particularly relevant for patients with ER poor tumours, who 
cannot benefit from endocrine therapies. The results of this study suggest that this guidance 
remains appropriate for an older population. 
 
These data suggest an increase in the use of chemotherapy in patients aged 70-79 since 
2002. Furthermore, disease characteristics associated with a high risk of recurrence are 
positively associated with receipt of chemotherapy. However, many patients for whom CT 
would be indicated still did not receive it, in particular, patients aged 80+. This may be 
justifiable given that older patients are more likely to die of other causes than of breast 
cancer, so gains in survival may be small in absolute terms and the risk of adverse events 
will be higher. On the one hand, if the reduction in breast cancer mortality observed for those 
aged 70-79 years is maintained in older patients, then an otherwise healthy 80 year old 
would still be expected to benefit from chemotherapy.  On the other hand, the risks of 
chemotherapy related morbidity and mortality will be higher and may outweigh any benefit. 
 
Research into the impact of chemotherapy on survival outcomes for older patients is limited 
as clinical trials typically exclude this group. Our findings are largely consistent with the 
EBCTCG meta-analyses (31), which demonstrated clear evidence of a benefit for patients 
receiving chemotherapy aged 50 to 69 at diagnosis, especially those with ER-poor tumours. 
However insufficient women aged 70+ were included in to draw conclusions about the 
benefits of chemotherapy in this population. A review of trials by Muss and colleagues (32) 
found similar reductions in breast cancer mortality for chemotherapy in younger and older 
patients with lymph-node positive cancer, but of 6487 patients only 159 (2%) were aged 70+. 
A retrospective analysis of  the US Surveillance, Epidemiology, and End Results Program 
(SEER) database (33) of 41,390 women aged 65+ demonstrated a significant survival benefit 
for chemotherapy in patients with ER-poor tumours and positive lymph nodes, but not in 
other groups. This is consistent with the findings of the current study, although not directly 
comparable because the age range is lower (>65 rather than >70 years) and the present 
analysis has used a different approach to looking at recurrence risk markers.  
 
A recent observational study (6) of the treatment decisions made by 24 UK NHS 
multidisciplinary teams (MDT) (N=803 patients) reported that the most commonly stated 
reasons for not offering chemotherapy were that “other treatments were more appropriate” 
(63%) and/or “perceived benefits too small” (54%), with co-morbidities (29%) and frailty 
(22%) also frequently cited, with considerable variation in decision making between 
practices. This suggests that some patients are probably under- or over-treated, highlighting 
the need for improved chemotherapy guidance in this age group. 
 
The analysis in the current study includes women aged 70+ who received surgery for early 
breast cancer from a region containing roughly 25% of the UK population. It includes 
recipients of adjuvant and neo-adjuvant chemotherapy but excludes recipients of primary 
endocrine therapy and neo-adjuvant endocrine therapy. This inclusion of the majority of 
cases of operable breast cancer is a key strength of the study and mitigates against biases 
associated with exclusion criteria in many randomised controlled trials, typically excluding 
older women and those with comorbidities. However, observational datasets may suffer from 
bias in treatment estimates due to differences in patient characteristics not captured by the 
multivariate model. This includes treatment selection based on disease severity. The data 
show that patients with more advanced disease and more aggressive tumours are more 
likely to receive chemotherapy. However, if any prognostic variables not in the dataset were 
used to determine treatment such as clinician and patient preference then this could bias the 
results, in either direction. Additional selection biases may arise from heterogeneity in health 
status of the cohort. The only data available on underlying health status other than age is 
comorbidity, scored using the HES-derived CCI and on cognitive function. These are likely to 
correlate with treatment choice and survival outcomes. However, this bias, if present, might 
be expected to impact on OS rather than BCSS. Further limitations include the lack of data 
on the chemotherapy regimens used, the dosage received or whether patients received a full 
course of chemotherapy. In addition, other outcomes, such as adverse events were not 
considered. 
 
Treatment selection may reflect the preference of the patient and/or the clinician. Interest 
has increased in the role of shared decision making in health care, defined as: ‘an approach 
where clinicians and patients share the best available evidence when faced with the task of 
making decisions, and where patients are supported to consider options, to achieve 
informed preferences” (34). The potential survival gains associated with CT have to be 
weighed against potential adverse events of treatment, which may reduce both life 
expectancy and quality of life.  The relative importance attached to different outcomes will 
vary by patient; patients should be assisted to make informed decisions and supported in the 
deliberation of their options.  
 
CONCLUSION 
 
This study demonstrates that the use of chemotherapy in two English regions increased 
between 2002 and 2012 in patients aged 70-79.  Although patients with high risk disease 
were more likely to receive chemotherapy, age remained a key determinant of treatment, 
once other factors were accounted for. The evidence suggests that adjuvant chemotherapy 
is associated with a reduction in the hazard of death from breast cancer, but it is not possible 
to determine the effect treatment has on overall life expectancy without additional 
information on the underlying health status of the patient. Nevertheless, these data suggest 
that for older patients at high risk of recurrence, chemotherapy may improve survival. 
Decisions on potential benefit for individual patients should be made on the basis of 
predicted life expectancy, treatment tolerance and patient preference. 
 
Supplementary information is available  
on the Clinical Oncology website. 
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Figure legends  
 
Figure 1: Consort diagram of patients included in the analysis 
 
Figure 2: Treatment received by age at diagnosis for patients with stage I,II,III or unknown 
stage. 
 
Figure 3: Patients aged 70-79 treated surgically who received adjuvant chemotherapy, by 
year of diagnosis.  Left: Total number of patients and number classified as high risk 
according to the ACHEW criteria by year.  The mean proportion (across years) of patients 
who are high risk is 45% (s.d. 2%).  Right: Proportion of patients. Shaded areas represent 
95% confidence intervals. 
 
Figure 4: Risk Category distribution by Treatment group. High risk patients were given a risk 
score according to how many of the risk indicators applied to them.  This figure shows the 
distribution of the resulting risk scores for the high risk members of the two treatment groups.   
 
Figure 5:  Kaplan Meier Curves for Breast Cancer Specific Survival by Risk Score. Even 
when considering only high risk patients, a naive KM analysis shows that patients who 
received chemotherapy tended to have worse survival than those who did not.  However, by 
limiting analysis to higher risk patients only (Risk score of 2 or more), the true benefit of 
chemotherapy is revealed. Shaded areas represent 95% confidence intervals. 
 
Figure S1: Example of a restricted cubic spline function with 5 knots.  The initial and final 
component functions are constrained to be linear with the remaining 4 being cubic.  Further 
constraints are imposed to ensure that the composite function is smooth at the knots. 
 
Figure S2: Time varying hazard ratio for age at diagnosis (per year over 70) as identified in 
the Royston-Parmar Model.   
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